• E Tabouret, C Bequet, E Denicolaï, M Barrié, I Nanni, P Metellus, Henri Dufour, O Chinot, and D Figarella-Branger.
• Aix-Marseille University, 13005, Marseille, France; APHM, Hopital de la Timone, Service d'anatomopathologie, 13005, Marseille, France; APHM, Hopital de la Timone, Service de Neuro-Oncologie, 13005, Marseille, France.
• Eur J Surg Oncol. 2015 Dec 1; 41 (12): 1685-90.

BackgroundPleomorphic xanthoastrocytoma (PXA) is a rare, low-grade glioma that frequently occurs in pediatric patients.ObjectiveTo analyze adult patients diagnosed with PXA and to search for pathological and molecular markers of diagnosis and prognosis.MethodsWe retrospectively included patients older than 16 years with PXA who were referred to our institution between October 2003 and September 2013. All pathological diagnoses were reviewed by a neuropathologist. Histological characteristics and immunostaining of GFAP, OLIG2, neurofilament, CD34, Ki67, p53, p16, and IDH1 R132H were analyzed. The following molecular alterations were analyzed: mutations of IDH1/2, BRAF and the histone H3.3 and the EGFR amplification. Clinical data, treatment modalities, and patient outcome were recorded.ResultsWe identified 16 adult patients with reviewed PXA diagnosis. No IDH neither histone H3.3 mutations were found; BRAF V600E mutation was recorded in six patients. Ten patients presented with anaplastic features. BRAF mutations were associated with lower Ki67, OLIG2 expression, and lack of p16 expression. Median PFS and OS were 41.5 months (95% CI: 11.4-71.6) and 71.4 months (95% CI: 15.5-127.3), respectively. BRAF mutation tended to be associated with greater PFS (p = 0.051), whereas anaplastic features were associated with minimal PFS (p = 0.042).ConclusionPXA in adults PXA may present features distinct from pediatric PXA. Anaplastic features and BRAF mutation may potentially identify specific subgroups with distinct prognoses.Copyright © 2015 Elsevier Ltd. All rights reserved.

31 keywords...

hide…